On October 9, 2025, Chengdu Newruit Medical Technology Co., Ltd. (hereinafter referred to as Newruit Medical) recently completed a Series D financing of approximately RMB 800 million. This round of financing is jointly led by Shenzhen Venture Capital and PICC Capital, with joint investment from well-known investment companies and financial institutions such as CNNC Fund, AstraZeneca Zhongjin Medical Industry Fund, Zhongqi Capital, Guangdong Traditional Chinese Medicine Big Health Fund, Nuclear Power High tech, Hunan Caixin Industry Fund, and Airport Venture Capital. Old shareholders Luzhou Starry Sky, Xintou Huace, and Rongtou Fund also continue to increase their investment.
Newruit Medical is a pioneer in the research and production of radioactive isotopes in China, with a layout of multiple scarce isotopes and initial results. The independently innovated Jialin @ germanium gallium generator not only steadily expands in the domestic market, but also successfully "goes global" and enters the Southeast Asian market, laying the foundation for the next step of expanding overseas markets; The first commercial 30MeVIKON proton accelerator in China has been built, which is about to achieve independent preparation and supply of more than 10 key nuclides such as germanium 168Gel and copper [225AC].
The full industry chain layout driven by accelerators is expected to be implemented; The development and production of popular nuclides such as radium [226Ra] and lead [212Pb] signify that Newruit Medical is patient-centered, driven by innovation, and writing a new chapter for domestic nuclear drugs to safeguard life.
Newruit Medical has 4 research pipelines in the clinical stage: NRT6003 injection, which is suitable for liver cancer indications, has entered the Sichuan phase clinical trial; NRT6008 injection suitable for pancreatic cancer indications is under construction/initial clinical trial; Two radiopharmaceuticals suitable for solid tumors have entered clinical trials (approved for clinical trials in both China and the United States). At the same time, there are multiple research and development pipelines in the preclinical development stage.
Shiyao Group's SYH2070 injection (double stranded small interfering RNA drug) has been approved for clinical use in the United States
On October 9, 2025, Shiyao Group (1093. HK) announced that its independently developed Class 1 chemical new drug 5YH2070 Injection (double stranded small interfering RNA (siRNA) drug) has been approved by the US Food and Drug Administration (FDA) for clinical trials in the United States. The product was also approved by the National Medical Products Administration of the People's Republic of China to conduct clinical trials in China in September 2025.
This product is an siRNA drug that achieves liver aviation targeted delivery by coupling acetylgalactosamine (GalINAc). It targets angiopoietin like protein 3 (ANGPTL3) through subcutaneous administration, effectively reducing ANGPTL3 levels. By optimizing the sequence and chemical modification strategy, this product achieves a more persistent gene silencing effect and is expected to become an siRNA drug with ultra long efficacy in reducing ANGPTL3.
It is suitable for treating high triglycerides or mixed hyperlipidemia and has the potential to effectively reduce the risk of residual cholesterol levels rising. Preclinical studies have shown that this product outperforms similar siRNA products in terms of drug activity and sustained efficacy, demonstrating differentiated advantages such as long-lasting drug effects, good safety, and high patient compliance. It has high clinical development value.
Paige Biotech authorizes GLP-1 weight loss drug in the Middle East and Africa
On October 10, 2025, Peugeot Biomedical (Hangzhou) Co., Ltd. announced that the company has entered into a non binding term sheet with PDCFZ-LLC of the United Arab Emirates, which contains the exclusive license of the company's product Visepegentide (PB-119), a subcutaneous injection type GLP-1 receptor agonist used for the treatment of type II diabetes and weight management.
According to the proposed terms, PDC will be granted an exclusive license to develop, distribute, market, and commercialize the product in the Middle East and Africa region. This license covers regional development, product registration, local production involving comprehensive technology transfer, and exclusive rights for comprehensive commercialization. The product will be sold in the region under PDC's trademark. According to public data, Visepegnatide (PB-119) is a weekly subcutaneous injection of GLP-1 receptor agonist independently developed by Peugeot Biologica, which is used to treat type 2 diabetes and weight management.
Compared with some similar products on the market, Visepegenatide (PB-119) exhibits excellent clinical characteristics, including good safety, tolerability, and significant key reduction and weight loss effects. Its innovative molecular design and long-term mechanism of action provide patients with more convenient and stable treatment options, representing the development direction of the new generation of GLP-1 therapy.
The Middle East and Africa region provides a huge and growing market for diabetes and obesity drugs. The high incidence rate and rising trend of these diseases highlight the huge unmet medical demand and commercial potential of innovative therapies such as PB-119.
